Source Count: 14 | Weighted Score: 38 | Source Confidence: [4/5] | Primary Tier: 2 | Last Updated: April 10, 2026
Keywords: cannabis, marijuana, THC, CBD, endocannabinoid system, anandamide, CB1, CB2, Raphael Mechoulam, consciousness, psychoactive, creativity, anxiety, psychosis, 2-AG
Category Tags: cannabis, endocannabinoid-system, consciousness, psychopharmacology, neuroscience
Cross-References: Y_1_01 — Psychedelics Overview · K_1_02 — Consciousness Neuroscience · Y_1_19 — Ibogaine Reset Mechanism

QUICK SUMMARY

Cannabis (Cannabis sativa) is the most widely used psychoactive substance in the world after alcohol and tobacco, consumed by an estimated 192 million people globally (2020, UNODC World Drug Report), and its effects on consciousness, cognition, and perception have been subjects of both ancient reverence and modern scientific investigation. KEY FINDING The foundational work in cannabis chemistry was accomplished by Raphael Mechoulam at the Hebrew University of Jerusalem, who in 1964 isolated and synthesized Δ9-tetrahydrocannabinol (THC) — the primary psychoactive component — published in the Journal of the American Chemical Society (vol. 86, pp. 1646–1647), a discovery that earned him the designation "father of cannabis research." Mechoulam's laboratory then discovered the endogenous cannabinoid system: anandamide (N-arachidonoylethanolamine), the first endogenous cannabinoid, was isolated from pig brain by Devane et al. (from Mechoulam's group) in 1992 (Science, vol. 258, pp. 1946–1949) — the name derives from the Sanskrit "ananda" (bliss). The second major endocannabinoid, 2-arachidonoylglycerol (2-AG), was identified by Mechoulam and Sugiura independently in 1995. The endocannabinoid system (ECS) comprises two primary receptors: CB1 (cloned 1990 by Matsuda et al., Nature, predominantly expressed in the brain — the most abundant G-protein coupled receptor in the human brain, concentrated in the hippocampus, cerebral cortex, basal ganglia, and cerebellum) and CB2 (cloned 1993, primarily in immune tissues). THC is a partial agonist at CB1, which explains its psychoactive effects; cannabidiol (CBD) has complex pharmacology including negative allosteric modulation of CB1, activation of 5-HT1A serotonin receptors, and inhibition of FAAH (the enzyme that breaks down anandamide), explaining its anxiolytic and anti-inflammatory properties without psychoactive intoxication. Cannabis's effects on consciousness are dose-dependent and bidirectional: low doses typically produce euphoria, perceptual enhancement (intensified colors, sounds, tastes), altered time perception (subjective time dilation), and enhanced associative thinking — while high doses, particularly of modern high-THC strains (>20% THC vs. historical ~3–5%), can produce anxiety, paranoia, depersonalization, and in vulnerable individuals, transient psychotic symptoms. A landmark longitudinal study by Di Forti et al. (2019, The Lancet Psychiatry) analyzing 901 first-episode psychosis patients across 11 European sites found that daily use of high-potency cannabis (>10% THC) was associated with a 5-fold increased odds of psychotic disorder — with the population-attributable fraction suggesting high-potency cannabis accounts for approximately 12% of first-episode psychosis cases across the study sites (rising to 30% in Amsterdam and 21% in London). The ECS is now understood to be a fundamental modulatory system involved in virtually every aspect of physiology: mood, memory consolidation (endocannabinoids in the hippocampus facilitate fear extinction — Marsicano et al., 2002, Nature), pain, appetite, sleep, and neuroprotection — making it one of the most important signaling systems in the body and a major therapeutic target.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 THC and Endocannabinoid Discovery

• Gaoni and Mechoulam (1964, JACS): isolated and synthesized THC — established the primary psychoactive compound in cannabis after decades of uncertainty
• Devane et al. (1992, Science): identified anandamide as the first endogenous cannabinoid in mammalian brain; Matsuda et al. (1990, Nature): cloned the CB1 receptor — these discoveries revealed that the brain has its own cannabis-like signaling system

1.2 CB1 Receptor Distribution and Function

• CB1 is the most abundant GPCR in the human brain — expressed at highest density in hippocampus (memory), basal ganglia (motor control), cerebellum (coordination), prefrontal cortex (executive function), and amygdala (emotion) — explaining cannabis's effects on memory, coordination, judgment, and mood
• CB1 activation reduces neurotransmitter release (functioning as a retrograde signal) — endocannabinoids serve as "demand-based" synaptic moderators

1.3 Cannabis and Psychosis Risk

• Di Forti et al. (2019, The Lancet Psychiatry, vol. 6, pp. 427–436): EU-GEI study across 11 sites — daily high-potency cannabis use associated with OR 4.8 for first-episode psychosis compared to never-users; dose-response relationship confirmed
• Earlier longitudinal data from Andréasson et al. (1987, The Lancet): Swedish conscript study of 45,570 men followed for 15 years — heavy cannabis use by age 18 associated with 6-fold increased schizophrenia risk

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Endocannabinoid-Mediated Fear Extinction

• Marsicano et al. (2002, Nature, vol. 418, pp. 530–534): demonstrated that CB1 receptor knockout mice showed impaired fear extinction — they could not "unlearn" conditioned fear responses — implicating the endocannabinoid system in adaptive forgetting and PTSD-relevant processes
• This has fueled interest in cannabis/cannabinoid-assisted therapy for PTSD — though clinical evidence is mixed, with nabilone (synthetic THC analog) showing some efficacy for PTSD-related nightmares

2.2 CBD as Therapeutic Agent

• Epidiolex (purified CBD) received FDA approval in June 2018 for treatment of Dravet syndrome and Lennox-Gastaut syndrome (severe childhood epilepsy) — the first cannabis-derived pharmaceutical approved in the US
• McGuire et al. (2018, American Journal of Psychiatry): randomized placebo-controlled trial of CBD (1,000 mg/day) in 88 schizophrenia patients — CBD group showed significant reduction in positive symptoms (PANSS score) — suggesting CBD may have antipsychotic properties opposite to THC's pro-psychotic effects

2.3 Altered Time Perception

• Cannabis consistently produces subjective time dilation — minutes feel like longer durations — demonstrated experimentally by Tinklenberg et al. (1976, Psychopharmacologia) and replicated in dozens of studies; the mechanism likely involves CB1 modulation of dopaminergic circuits in the basal ganglia and supplementary motor area involved in interval timing

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Cannabis and Creativity

• Studies on cannabis and creativity show mixed results — Schafer et al. (2012, Consciousness and Cognition) found that cannabis increased "divergent thinking" scores (a creativity measure) in low-creativity individuals but not high-creativity individuals — the relationship is complex and dose-dependent; high doses impair the executive function needed to structure creative output

3.2 Entourage Effect

• Russo (2011, British Journal of Pharmacology): proposed that cannabis's therapeutic effects depend on the interaction of THC, CBD, terpenes, and other minor cannabinoids acting synergistically (the "entourage effect") — while theoretically elegant and supported by some preclinical data, rigorous clinical evidence comparing whole-plant to single-molecule cannabis preparations is limited

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Cannabis Is Completely Harmless

• DEBUNKED While less acutely dangerous than many substances, cannabis carries documented risks: psychosis in vulnerable individuals, cannabis use disorder (affecting approximately 9% of users, 17% of those who start in adolescence — Anthony et al., 1994, Experimental and Clinical Psychopharmacology), cognitive impairment with heavy adolescent use, and respiratory harm from smoked cannabis

4.2 Cannabis Cures Cancer

• DEBUNKED While cannabinoids show anti-tumor effects in cell culture and some animal models, there is no clinical evidence that cannabis cures cancer in humans — the National Cancer Institute and all major oncology organizations emphasize that cannabis may help manage cancer symptoms (pain, nausea, appetite) but is not an anti-cancer treatment

Counter-Arguments & Criticisms

Causation vs. Association in Psychosis

• Researchers argue that the cannabis-psychosis association may be partly confounded by genetic vulnerability — individuals predisposed to psychosis may also be predisposed to seek cannabis (Gage et al., 2017, Psychological Medicine: Mendelian randomization published findings demonstrate bidirectional relationship); though Di Forti's large multi-site data strengthens the causal interpretation

Potency Escalation Concern

• Modern cannabis strains (average 15–25% THC, some exceeding 30%) are dramatically more potent than those available historically (~3–5% THC in the 1970s) — meanwhile, CBD content has decreased — raising concerns that modern cannabis research may underestimate and historical research overestimate the safety profile

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Gaoni, Yechiel; Raphael Mechoulam | 1964 | "Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish" | Journal of the American Chemical Society | ∅ | 86.8::1646–1647 | ∅ | ∅ | doi:10.1021/ja01062a046 | ∅ | ∅ | ∅
2. Devane, William, et al | 1992 | "Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor" | Science | ∅ | 258.5090::1946–1949 | ∅ | ∅ | doi:10.1126/science.1470919 | ∅ | ∅ | ∅
3. Matsuda, Lisa, et al | 1990 | "Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA" | Nature | ∅ | 346.6284::561–564 | ∅ | ∅ | doi:10.1038/346561a0 | ∅ | ∅ | ∅
4. Di Forti, Marta, et al. . )30048-3 | 2019 | "The Contribution of Cannabis Use to Variation in the Incidence of Psychotic Disorder across Europe" | The Lancet Psychiatry | ∅ | 6.5::427–436 | ∅ | ∅ | doi:10.1016/S2215-0366(19 | ∅ | ∅ | ∅
5. Marsicano, Giovanni, et al | 2002 | "The Endogenous Cannabinoid System Controls Extinction of Aversive Memories" | Nature | ∅ | 418.6897::530–534 | ∅ | ∅ | doi:10.1038/nature00839 | ∅ | ∅ | ∅
6. McGuire, Philip, et al | 2018 | "Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia" | American Journal of Psychiatry | ∅ | 175.3::225–231 | ∅ | ∅ | doi:10.1176/appi.ajp.2017.17030325 | ∅ | ∅ | ∅
7. Russo, Ethan | 2011 | "Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects" | British Journal of Pharmacology | ∅ | 163.7::1344–1364 | ∅ | ∅ | doi:10.1111/j.1476-5381.2011.01238.x | ∅ | ∅ | ∅
8. Andréasson, Sven, et al. . )92620-1 | 1987 | "Cannabis and Schizophrenia: A Longitudinal Study of Swedish Conscripts" | The Lancet | ∅ | 330.8574::1483–1486 | ∅ | ∅ | doi:10.1016/S0140-6736(87 | ∅ | ∅ | ∅
9. Mechoulam, Raphael; Lumir Hanuš | 2000 | "A Historical Overview of Chemical Research on Cannabinoids" | Chemistry and Physics of Lipids | ∅ | 2::1–13 | 108.1 . )00184-5 | ∅ | doi:10.1016/S0009-3084(00 | ∅ | ∅ | ∅
10. Schafer, Gráinne, et al | 2012 | "Investigating the Interaction Between Schizotypy, Divergent Thinking and Cannabis Use" | Consciousness and Cognition | ∅ | 21.1::292–298 | ∅ | ∅ | doi:10.1016/j.concog.2011.11.009 | ∅ | ∅ | ∅
11. Anthony, James, Lynn Warner; Ronald Kessler | 1994 | "Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants" | Experimental and Clinical Psychopharmacology | ∅ | 2.3::244–268 | ∅ | ∅ | doi:10.1037/1064-1297.2.3.244 | ∅ | ∅ | ∅
12. Tinklenberg, Jared, et al | 1976 | "Cannabis and Alcohol Effects on Assaultiveness in Adolescent Delinquents" | Annals of the New York Academy of Sciences | ∅ | 282::85–94 | ∅ | ∅ | doi:10.1111/j.1749-6632.1976.tb49889.x | ∅ | ∅ | ∅
13. Devinsky, Orrin, et al | 2017 | "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome" | New England Journal of Medicine | ∅ | 376.21::2011–2020 | ∅ | ∅ | doi:10.1056/NEJMoa1611618 | ∅ | ∅ | ∅
14. Lu, Hui-Chen; Ken Mackie | 2016 | "An Introduction to the Endogenous Cannabinoid System" | Biological Psychiatry | ∅ | 79.7::516–525 | ∅ | ∅ | doi:10.1016/j.biopsych.2015.07.028 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 10, 2026